Cancer HorizonsAll NewsBlogsCaregivingDiet and ExerciseFinancialPsychosocialRecipesSexual HealthSide EffectSponsoredSurvivorship
All VideosCURE ConnectionsCURE Expert Connections®CURE Speaking OutCURE TVEducated Patient Sound BitesOn Demand: Webinars
Conference Coverage Conference Listing
CURE AdventuresCURE AwardsEducated Patient In Person EducationEducated Patient Virtual Education
Advocacy GroupsArt GalleryClinical Trial CornerHeal®PartnersPodcastsPublicationsShare Your Story
Subscribe
Blood CancersBlood CancersBlood CancersBlood Cancers
Brain Cancer
Breast CancerBreast Cancer
Childhood Cancers
Gastrointestinal CancersGastrointestinal CancersGastrointestinal CancersGastrointestinal CancersGastrointestinal CancersGastrointestinal CancersGastrointestinal CancersGastrointestinal Cancers
Genitourinary CancersGenitourinary CancersGenitourinary CancersGenitourinary CancersGenitourinary Cancers
Gynecologic CancerGynecologic CancerGynecologic CancerGynecologic CancerGynecologic Cancer
Head & Neck Cancer
Immunotherapy
LeukemiaLeukemiaLeukemia
Lung CancerLung Cancer
LymphomaLymphomaLymphomaLymphomaLymphoma
Myeloma
Rare CancersRare CancersRare CancersRare Cancers
Sarcoma
Skin CancerSkin Cancer
Thyroid Cancer
Spotlight -
  • Blogs
  • Breast Cancer Webinar Series
  • Cancer Horizons
  • Clinical Trial Corner
  • Heal®
  • Publications
  • Videos
Blood CancersBlood CancersBlood CancersBlood Cancers
Brain Cancer
Breast CancerBreast Cancer
Childhood Cancers
Gastrointestinal CancersGastrointestinal CancersGastrointestinal CancersGastrointestinal CancersGastrointestinal CancersGastrointestinal CancersGastrointestinal CancersGastrointestinal Cancers
Genitourinary CancersGenitourinary CancersGenitourinary CancersGenitourinary CancersGenitourinary Cancers
Gynecologic CancerGynecologic CancerGynecologic CancerGynecologic CancerGynecologic Cancer
Head & Neck Cancer
Immunotherapy
LeukemiaLeukemiaLeukemia
Lung CancerLung Cancer
LymphomaLymphomaLymphomaLymphomaLymphoma
Myeloma
Rare CancersRare CancersRare CancersRare Cancers
Sarcoma
Skin CancerSkin Cancer
Thyroid Cancer
    • Subscribe
Advertisement

News

Article

May 2, 2025

Pretreatment Baseline Screening for Breast Cancer-Related Lymphedema

Author(s):

Spencer Feldman

Fact checked by:

Ryan Scott

Key Takeaways

  • Baseline assessments before breast cancer treatment improve early detection of lymphedema, as shown by the PREVENT trial involving 1,200 patients.
  • Without pre-treatment baselines, up to 88% of early lymphedema cases could be missed, highlighting the importance of early measurement.
  • The SOZO device, an FDA-cleared bioimpedance tool, effectively reduces lymphedema progression and is recommended in clinical guidelines.
  • Updated NCCN guidelines emphasize baseline screening for patients with lymphedema risk factors, reinforcing early detection's importance.
SHOW MORE

New results from a breast cancer-related lymphedema study show the importance of measuring fluid and body composition before treatment begins.

New results from a breast cancer-related lymphedema study show the importance of measuring fluid and body composition before treatment begins: © H_Ko - stock.adobe.com.

New results from a breast cancer-related lymphedema study show the importance of measuring fluid and body composition before treatment begins: © H_Ko - stock.adobe.com.

Baseline assessments conducted before breast cancer treatment increased the chance of identifying breast cancer-related lymphedema at an earlier stage after treatment, according to data from the PREVENT trial, which were shared in a news release from ImpediMed.

Without a pretreatment baseline, up to 71% of patients monitored with bioimpedance spectroscopy and up to 88% of those monitored with tape measure would not have been identified as having early signs of lymphedema, potentially missing the opportunity for earlier, more effective treatment, according to findings from PREVENT. Notably, this trial is the largest randomized controlled trial to evaluate lymphedema prevention, the news release emphasized.

PREVENT evaluates 1,200 patients and tracks progression to chronic breast cancer-related lymphedema following early intervention, as assessed by both bioimpedance spectroscopy and traditional tape measurement.

"This evidence reinforces the critical importance of establishing an easy-to-perform, baseline measurement for fluid and body composition, one that improves the likelihood of detecting [breast cancer-related lymphedema] as early as possible so lymphedema treatment can begin at its most reversible stages," Dr. Steven L. Chen, the study’s lead author and ImpediMed's chief medical officer, said in the news release. "These findings highlight the importance of paying attention to lymphedema risk even as the cancer treatment is being planned."

ImpediMed offers the only U.S. Food and Drug Administration (FDA)-cleared bioimpedance spectroscopy solution for the clinical assessment of lymphedema — SOZO Digital Health Program. The platform is now recommended nationwide in clinical practice guidelines and is generally accepted and recognized for accurate and effective screening of lymphedema.

SOZO, a noninvasive bioimpedance spectroscopy device, provides a fluid and tissue snapshot in under 30 seconds using 256 data points across multiple frequencies. Cleared by the FDA and designed for use across health systems, SOZO helps detect secondary lymphedema, track fluid status in patients with heart or kidney failure and support overall health monitoring.

Furthermore, the National Comprehensive Cancer Network updated its Breast Cancer Clinical Practice Guidelines recently, which advises on baseline pretreatment screening for patients with lymphedema risk factors. This reinforces the importance of measuring at baseline to support early detection of lymphedema.

"I'm proud to support research that highlights the benefits of closer monitoring for breast cancer survivors," Scott Long, newly appointed senior vice president of sales at ImpediMed, said in the news release. "It's rewarding to see survivorship care gaining momentum — something I've championed throughout my 30-year career in breast cancer biopsy and device development."

More on the PREVENT Trial

The PREVENT trial enrolled patients across 10 sites in the U.S. and Australia, including 13 hospitals such as Vanderbilt University, Mayo Clinic and The University of Texas MD Anderson Cancer Center. Conducted over six and a half years, the study followed patients for up to three years to evaluate whether early intervention after subclinical detection of extracellular fluid buildup via bioimpedance spectroscopy could reduce lymphedema progression compared with detection with a tape measure. The findings were published in Lymphatic Research and Biology.

Results showed a 7.9% rate of chronic lymphedema in patients monitored with L-Dex technology and treated early with compression garments compared with 19.2% in those assessed with tape measure. The 11.3% difference was statistically significant and represented a 59% relative reduction in progression at three years, offering meaningful clinical benefit for patients and clinicians, as per the release.

Additional insights based on these findings will be presented during a poster session at the 2025 American Society of Breast Surgeons Annual Meeting in Las Vegas, Nevada, on Friday, May 2, at 6:00 p.m. The study is titled, "The Importance of a Pre-Treatment Baseline When Screening Patients for Breast Cancer–Related Lymphedema." The study will be presented by Chen.

For more news on cancer updates, research and education, don’t forget to subscribe to CURE®’s newsletters here.

Newsletter

Stay up to date on cancer updates, research and education

Subscribe Now!
Related Videos
Picture of Dr. Pouneh Razavi
Image of a woman wearing a headband and glasses
Image of doctor.
Image of woman.
Image of woman.
Image of Doctor.
Registered nurse Patricia Jakel emphasizes the importance of educating patients on evolving breast cancer research and the need for routine screenings.
Dr. Debu Tripathy highlights the importance of staying informed on breast cancer advancements and how this empowers patients to make informed decisions.
Image od grey haired Doctor.
Related Content
Advertisement
Breast.
May 13th 2025

Understanding the Unique Task of Treating Older Patients With Breast Cancer

Ryan Scott
Dr. Hyman B. Muss discusses the unique challenges that older patients with breast cancer face during and after treatment for their disease.
cancer horizons podcast logo: a white microphone on a blue background
March 4th 2024

Cannabis Talks During Cancer, Cardiometabolic Comorbidities and Current Research

Alex Biese Brielle Benyon
In addition to a breakthrough therapy designation for a lung cancer drug, this week we’ll be talking a lot about additional side effects and health conditions that may come with a cancer diagnosis, and how to manage them.
Breast cancer cracked me open but didn’t break me: © stock.adobe.com.
May 13th 2025

Cracked, Not Broken: Life After Breast Cancer

Tianja Grant
Breast cancer cracked me open but didn’t break me — it gave me voice, purpose and courage to dream boldly, live fully and speak up for those who can’t.
Guidelines for Childhood Neuroblastoma, FDA Decisions and More
February 12th 2024

Guidelines for Childhood Neuroblastoma, FDA Decisions and More

Alex Biese Brielle Benyon
Last week, we saw a few moving parts in the regulatory space, from new NCCN guidelines for pediatric neuroblastoma treatment to FDA Fast Tracks and Priority Reviews
Image of woman holding her chest.
May 10th 2025

Personalized Breast Cancer Care for Older Adults Goes Beyond Age

Ryan Scott
Dr. Hyman B. Muss discusses the unique facets of care that should inform personalized treatment decision-making for older patients with breast cancer.
Patti McGee is an author, a massage therapist and breast cancer survivor of 20 years. Catch up on all of Patti's blogs here!
May 8th 2025

Celebrating Nurses Week: The Heart and Soul of Our Cancer Community

Patti McGee
I’m 22 years out from breast cancer and forever grateful for the nurses who gave me not just treatment but friendship, laughter and a community of hope.
Related Content
Advertisement
Breast.
May 13th 2025

Understanding the Unique Task of Treating Older Patients With Breast Cancer

Ryan Scott
Dr. Hyman B. Muss discusses the unique challenges that older patients with breast cancer face during and after treatment for their disease.
cancer horizons podcast logo: a white microphone on a blue background
March 4th 2024

Cannabis Talks During Cancer, Cardiometabolic Comorbidities and Current Research

Alex Biese Brielle Benyon
In addition to a breakthrough therapy designation for a lung cancer drug, this week we’ll be talking a lot about additional side effects and health conditions that may come with a cancer diagnosis, and how to manage them.
Breast cancer cracked me open but didn’t break me: © stock.adobe.com.
May 13th 2025

Cracked, Not Broken: Life After Breast Cancer

Tianja Grant
Breast cancer cracked me open but didn’t break me — it gave me voice, purpose and courage to dream boldly, live fully and speak up for those who can’t.
Guidelines for Childhood Neuroblastoma, FDA Decisions and More
February 12th 2024

Guidelines for Childhood Neuroblastoma, FDA Decisions and More

Alex Biese Brielle Benyon
Last week, we saw a few moving parts in the regulatory space, from new NCCN guidelines for pediatric neuroblastoma treatment to FDA Fast Tracks and Priority Reviews
Image of woman holding her chest.
May 10th 2025

Personalized Breast Cancer Care for Older Adults Goes Beyond Age

Ryan Scott
Dr. Hyman B. Muss discusses the unique facets of care that should inform personalized treatment decision-making for older patients with breast cancer.
Patti McGee is an author, a massage therapist and breast cancer survivor of 20 years. Catch up on all of Patti's blogs here!
May 8th 2025

Celebrating Nurses Week: The Heart and Soul of Our Cancer Community

Patti McGee
I’m 22 years out from breast cancer and forever grateful for the nurses who gave me not just treatment but friendship, laughter and a community of hope.
About Us
Advertise / Support
Editorial Board
Contact Us
CancerNetwork.com
TargetedOnc.com
OncLive.com
OncNursingNews.com
Terms & Conditions
Privacy
Do Not Sell My Information
Contact Info

2 Commerce Drive
Cranbury, NJ 08512

609-716-7777

© 2025 MJH Life Sciences

All rights reserved.